articaine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
local anaesthetics 3070 23964-58-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • articaine
  • carticaine
  • articaine hydrochloride
  • articaine HCl
A thiophene-containing local anesthetic pharmacologically similar to MEPIVACAINE.
  • Molecular weight: 284.37
  • Formula: C13H20N2O3S
  • CLOGP: 1.98
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 67.43
  • ALOGS: -4
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 7.70 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 126.70 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.46 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.98 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT2,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK 48
kinase-selectivity-class AXL,BRAF,DDR1,GRK2,MAP2K6,MAPK7,STK33,TEK,TTK 9
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
April 3, 2000 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sinobronchitis 107.44 97.03 14 542 468 110588275

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N01BB08 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, LOCAL
Amides
ATC N01BB58 NERVOUS SYSTEM
ANESTHETICS
ANESTHETICS, LOCAL
Amides
FDA CS M0000897 Amides
MeSH PA D000777 Anesthetics
MeSH PA D000779 Anesthetics, Local
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018689 Sensory System Agents
FDA EPC N0000175682 Amide Local Anesthetic
FDA PE N0000175976 Local Anesthesia
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:67079 anti-inflammatory agent

Related Drugs by ATC class:

N01BB Amides 10 drugs
bupivacainebutanilicainecinchocaineetidocainelevobupivacainelidocainemeloxicammepivacaineprilocaineropivacaine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Local anesthesia, by infiltration indication 44596000
Administration of Local Anesthetic Nerve Block indication
Sinus tachycardia contraindication 11092001
Myocardial infarction contraindication 22298006 DOID:5844
Parkinsonism contraindication 32798002
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Cerebral arteriosclerosis contraindication 65312002
Diabetes mellitus contraindication 73211009 DOID:9351
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Bleeding contraindication 131148009
Angina pectoris contraindication 194828000
Primary dilated cardiomyopathy contraindication 195021004
Disease of liver contraindication 235856003 DOID:409
Deficiency of cholinesterase contraindication 360607009
Angle-closure glaucoma contraindication 392291006 DOID:13550
Disorder of coronary artery contraindication 414024009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.35 acidic
pKa2 7.9 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 8% BASE CYKLX THEA PHARMA N218643 Aug. 15, 2025 DISCN SOLUTION/DROPS OPHTHALMIC 11096922 March 27, 2039 METHOD OF ANESTHETIZING AN OCULAR SURFACE VIA TOPICAL ADMINISTRATION PRIOR TO OCULAR PROCEDURES AND/OR INTRAOCULAR INJECTIONS
EQ 8% BASE CYKLX THEA PHARMA N218643 Aug. 15, 2025 DISCN SOLUTION/DROPS OPHTHALMIC 11826347 March 27, 2039 METHOD OF ANESTHETIZING AN OCULAR SURFACE VIA TOPICAL ADMINISTRATION PRIOR TO OCULAR PROCEDURES AND/OR INTRAOCULAR INJECTIONS
EQ 8% BASE CYKLX THEA PHARMA N218643 Aug. 15, 2025 DISCN SOLUTION/DROPS OPHTHALMIC 12403126 March 27, 2039 METHOD OF ANESTHETIZING AN OCULAR SURFACE PRIOR TO OCULAR PROCEDURES AND/OR INTRAOCULAR INJECTIONS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 8% BASE CYKLX THEA PHARMA N218643 Aug. 15, 2025 DISCN SOLUTION/DROPS OPHTHALMIC Aug. 15, 2028 NEW PRODUCT

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel BLOCKER IC50 4.29 CHEMBL CHEMBL

External reference:

IDSource
4021368 VUID
N0000148787 NUI
D02991 KEGG_DRUG
23964-57-0 SECONDARY_CAS_RN
4021368 VANDF
C1608295 UMLSCUI
CHEBI:748399 CHEBI
CHEMBL1093 ChEMBL_ID
CHEMBL1200819 ChEMBL_ID
DB09009 DRUGBANK_ID
3193 INN_ID
D3SQ406G9X UNII
32170 PUBCHEM_CID
2117 RXNORM
14782 MMSL
d04536 MMSL
003780 NDDF
003799 NDDF
005096 NDDF
410851000 SNOMEDCT_US
703107005 SNOMEDCT_US
D002355 MESH_DESCRIPTOR_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zorcaine HUMAN PRESCRIPTION DRUG LABEL 2 0362-0830 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
Septocaine and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0362-9048 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA 29 sections
Septocaine and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0362-9049 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA 29 sections
Articaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0404-6620 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
Articaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 0404-6625 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
ARTICAINE HUMAN PRESCRIPTION DRUG LABEL 2 43128-101 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
ARTICAINE HUMAN PRESCRIPTION DRUG LABEL 2 43128-102 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
Articaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 43498-816 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
Articaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 43498-993 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
Orabloc HUMAN PRESCRIPTION DRUG LABEL 2 45146-110 INJECTION 40 mg SUBMUCOSAL NDA 29 sections
Orabloc HUMAN PRESCRIPTION DRUG LABEL 2 45146-120 INJECTION 40 mg SUBMUCOSAL NDA 29 sections
ARTICAINE HUMAN PRESCRIPTION DRUG LABEL 2 50227-1040 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
ARTICAINE HUMAN PRESCRIPTION DRUG LABEL 2 50227-1050 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
ARTICAINE HUMAN PRESCRIPTION DRUG LABEL 2 51004-0102 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
ARTICAINE HUMAN PRESCRIPTION DRUG LABEL 2 51004-1010 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
ARTICAINE HUMAN PRESCRIPTION DRUG LABEL 2 51004-1040 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
ARTICAINE HUMAN PRESCRIPTION DRUG LABEL 2 51004-4175 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
ARTICAINE HUMAN PRESCRIPTION DRUG LABEL 2 51004-4185 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
Articaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 51004-6620 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
Articaine Hydrochloride and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 51004-6625 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
Ultacan Forte HUMAN PRESCRIPTION DRUG LABEL 2 52120-100 INJECTION, SOLUTION 40 mg SUBMUCOSAL ANDA 26 sections
Ultacan HUMAN PRESCRIPTION DRUG LABEL 2 52120-200 INJECTION, SOLUTION 40 mg SUBMUCOSAL ANDA 26 sections
Articadent HUMAN PRESCRIPTION DRUG LABEL 2 66312-601 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 30 sections
Articadent HUMAN PRESCRIPTION DRUG LABEL 2 66312-602 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 30 sections
ARTICAINE HUMAN PRESCRIPTION DRUG LABEL 2 66975-417 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
ARTICAINE HUMAN PRESCRIPTION DRUG LABEL 2 66975-418 INJECTION, SOLUTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
Articaine HCl and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 67239-0209 INJECTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections
Articaine HCl and Epinephrine HUMAN PRESCRIPTION DRUG LABEL 2 67239-0210 INJECTION 40 mg SUBMUCOSAL NDA authorized generic 29 sections